Cataract News and Research RSS Feed - Cataract News and Research

A cataract is a clouding of the lens in the eye that affects vision. Most cataracts are related to aging. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery.

A cataract can occur in either or both eyes. It cannot spread from one eye to the other.
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]
University of Delaware researchers identify prime suspects in cataract formation

University of Delaware researchers identify prime suspects in cataract formation

When cataracts encroach on the eyes, the only effective remedy is to surgically replace the eyes' lenses with synthetic substitutes. But what if scientists found a way to delay or prevent cataracts from forming in the first place? Researchers at the University of Delaware may have found such an opportunity by identifying the prime suspects in the formation of cataracts - deficiency of two genes that encode regulatory proteins. [More]
Iowa's advanced driving simulator to help assess newly developed artificial lens for cataract patients

Iowa's advanced driving simulator to help assess newly developed artificial lens for cataract patients

A miniature version of the University of Iowa's advanced driving simulator will participate in a clinical trial later this year to assess a patient's driving ability after cataract surgery. [More]
Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery. [More]
FE65 and FE65L1 proteins may become therapeutic target for muscular dystrophy, cataracts and Alzheimer's

FE65 and FE65L1 proteins may become therapeutic target for muscular dystrophy, cataracts and Alzheimer's

Amyloid precursor protein (APP), a key protein implicated in the development Alzheimer's disease, may play an important role in eye and muscle health. In a new report published in the June 2015 issue of The FASEB Journal, scientists have discovered that when proteins that bind to the APP, called FE65 and FE65L1, are deleted, they cause cataracts and muscle weakness in mice. [More]
Despite low value and high costs, certain preoperative tests still common in U.S.

Despite low value and high costs, certain preoperative tests still common in U.S.

Professional physician associations consider certain routine tests before elective surgery to be of low value and high cost, and have sought to discourage their utilization. [More]
New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

New York Eye and Ear Infirmary of Mount Sinai joins with the International Orthoptic Association to observe June 1st as World Orthoptics Day. [More]
Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

The Centers for Medicare & Medicaid Services today released to the public data relating to 2013 Medicare payments made to physicians and other providers. In response, the American Academy of Ophthalmology is providing necessary context for the reimbursement data, which in its raw form are often complex and difficult to understand. [More]
Metformin can reduce risk of open-angle glaucoma in people with diabetes

Metformin can reduce risk of open-angle glaucoma in people with diabetes

Taking the medication metformin hydrochloride was associated with reduced risk of developing the sight-threatening disease open-angle glaucoma in people with diabetes, according to a study published online by JAMA Ophthalmology. [More]
Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. [More]
Many Medicare patients undergo unnecessary routine preoperative tests before cataract surgery

Many Medicare patients undergo unnecessary routine preoperative tests before cataract surgery

More than half of all Medicare patients who have cataract surgery undergo unnecessary routine preoperative testing, despite strong evidence that these tests are usually not beneficial and increase national health care costs, reports a study published on April 16 in The New England Journal of Medicine. [More]

Haag-Streit Surgical receives FDA 510(k) clearance for intraoperative-OCT camera

HAAG-STREIT SURGICAL announced its intraoperative-OCT camera has received 510(k) clearance from the U.S. Food and Drug Administration for marketing on the largest medical device market in the world. [More]

Omeros announces commercial availability of Omidria in U.S.

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%. [More]
UC Davis' John S. Werner wins 2015 Verriest Medal from International Colour Vision Society

UC Davis' John S. Werner wins 2015 Verriest Medal from International Colour Vision Society

John S. Werner, a UC Davis neuroscientist and international authority on visual perception, has been selected to receive the 2015 Verriest Medal from the International Colour Vision Society for his contributions to understanding the structural and functional basis of color vision, how and why vision changes across the life span, and factors that contribute to loss of vision associated with disease. He will receive the award at the society's biennial symposium in Sendai, Japan, in July. [More]
Study sheds light on cataract development

Study sheds light on cataract development

The motion of coins in a "Penny Pusher" carnival game is similar to the movement of cells in the eye's lens, as described in a new study published in Investigative Ophthalmology & Visual Science (IOVS). [More]

IRIDEX's new Cyclo G6 laser system now available for treatment of patients with glaucoma

IRIDEX Corporation announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma dedicated laser along with a family of single use probes, including the newly patented MicroPulse P3 disposable. [More]
Medicine-loaded nanoparticles could help patients achieve corneal transplant success

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families. [More]
Severe mortality-associated diseases less prevalent in members of long-lived families

Severe mortality-associated diseases less prevalent in members of long-lived families

Recent research from the Long Life Family Study (LLFS) confirms that severe mortality-associated diseases are less prevalent in the families of long-lived individuals than in the general population. The Journals of Gerontology, Series A will publish these findings in the article titled, "Are Members of Long-Lived Families Healthier than Their Equally Long-Lived Peers? Evidence from the Long Life Family Study" on March 5, 2015. [More]
NHS savings plan led to cuts in some ‘ineffective’ treatments

NHS savings plan led to cuts in some ‘ineffective’ treatments

The drive to reduce NHS spending led to a drop in some treatments considered ‘low-value’, according to new research. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Advertisement
Advertisement